angry birds online game

angry birds online game WHIM Syndrome Pipeline Analysis 2024: FDA Approvals and Emerging Therapies, Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments | X4 Pharmaceuticals, NIAID 12-09-2024 09:35 PM CET | Health & Medicine Press release from: DelveInsight Business Research (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, WHIM Syndrome pipeline constitutes key companies continuously working towards developing WHIM Syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "WHIM Syndrome Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the WHIM Syndrome Market. The WHIM Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. Some of the key takeaways from the WHIM Syndrome Pipeline Report: https://www.delveinsight.com/sample-request/whim-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr •Companies across the globe are diligently working toward developing novel WHIM Syndrome treatment therapies with a considerable amount of success over the years. •WHIM Syndrome companies working in the treatment market are X4 Pharmaceuticals, NIAID, and others, are developing therapies for the WHIM Syndrome treatment •Emerging WHIM Syndrome therapies in the different phases of clinical trials are- Mavorixafor, Plerixafor, X4P-001, and others are expected to have a significant impact on the WHIM Syndrome market in the coming years. •In November 2024, X4 anticipates submitting a Marketing Authorization Application (MAA) for the approval of mavorixafor in WHIM syndrome to the European Medicines Agency (EMA) by early 2025. The company is also exploring other potential opportunities in regions where it can effectively leverage its U.S. approval. WHIM Syndrome Overview WHIM Syndrome is a rare genetic disorder caused by mutations in the CXCR4 gene. It is characterized by four main symptoms: warts, hypogammaglobulinemia (low levels of antibodies), infections, and myelokathexis (a defect in the release of white blood cells). These immune system abnormalities make individuals with WHIM Syndrome more susceptible to infections and other complications. The condition can also lead to hematological issues, such as an abnormal number of white blood cells. Treatment may include immunoglobulin replacement therapy, antibiotics, and, in some cases, targeted therapies to address the underlying genetic mutation. Get a Free Sample PDF Report to know more about WHIM Syndrome Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/whim-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Emerging WHIM Syndrome Drugs Under Different Phases of Clinical Development Include: •Mavorixafor: X4 Pharmaceuticals •Plerixafor: NIAID •X4P-001: X4 Pharmaceuticals WHIM Syndrome Pipeline Therapeutics Assessment •WHIM Syndrome Assessment by Product Type •WHIM Syndrome By Stage and Product Type •WHIM Syndrome Assessment by Route of Administration •WHIM Syndrome By Stage and Route of Administration •WHIM Syndrome Assessment by Molecule Type •WHIM Syndrome by Stage and Molecule Type DelveInsight's WHIM Syndrome Report covers around products under different phases of clinical development like •Late-stage products (Phase III) •Mid-stage products (Phase II) •Early-stage product (Phase I) •Pre-clinical and Discovery stage candidates •Discontinued & Inactive candidates •Route of Administration Further WHIM Syndrome product details are provided in the report. Download the WHIM Syndrome pipeline report to learn more about the emerging WHIM Syndrome therapies at: https://www.delveinsight.com/sample-request/whim-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the key companies in the WHIM Syndrome Therapeutics Market include: Key companies developing therapies for WHIM Syndrome are - GSK plc, Bristol Myers Squibb Company, F-Hoffmann La Roche Ltd., Pfizer Inc., Johnson and Johnson Services, Inc., X4 Pharmaceuticals, National Institute of Allergy and Infectious Diseases, Horizon Therapeutics plc, Amgen, Leadiant Biosciences, and others. WHIM Syndrome Pipeline Analysis: The WHIM Syndrome pipeline report provides insights into •The report provides detailed insights about companies that are developing therapies for the treatment of WHIM Syndrome with aggregate therapies developed by each company for the same. •It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for WHIM Syndrome Treatment. •WHIM Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. •WHIM Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. •Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the WHIM Syndrome market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Download Sample PDF Report to know more about WHIM Syndrome drugs and therapies- https://www.delveinsight.com/sample-request/whim-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr WHIM Syndrome Pipeline Market Strengths •Emerging drugs like mavorixafor in late-stage clinical development with strong clinical data for treating neutropenia, lymphopenia, sustained improvements in infections and warts in WHIM syndrome patients •Support from regulatory authorities by granting ODD status, Breakthrough Designations, and rare pediatric disease designations to encourage clinical drug development for the treatment of ultra-rare diseases WHIM Syndrome Pipeline Market Opportunities •There are no disease-specific approved therapies for the treatment of WHIM syndrome •The first product approved for the treatment of WHIM is likely to get a first-mover advantage across the 7MM •The current management of the disease includes only symptomatic treatments and does not affect the underlying cause of the disease CXCR4 mutation •Emerging therapeutic options like Mavorixafor could expand their label to treat severe chronic neutropenia, CVID, and lymphopenia Scope of WHIM Syndrome Pipeline Drug Insight •Coverage: Global •Key WHIM Syndrome Companies: X4 Pharmaceuticals, NIAID, and others •Key WHIM Syndrome Therapies: Mavorixafor, Plerixafor, X4P-001, and others •WHIM Syndrome Therapeutic Assessment: WHIM Syndrome current marketed and WHIM Syndrome emerging therapies •WHIM Syndrome Market Dynamics: WHIM Syndrome market drivers and WHIM Syndrome market barriers Request for Sample PDF Report for WHIM Syndrome Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/whim-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Table of Contents 1. WHIM Syndrome Report Introduction 2. WHIM Syndrome Executive Summary 3. WHIM Syndrome Overview 4. WHIM Syndrome- Analytical Perspective In-depth Commercial Assessment 5. WHIM Syndrome Pipeline Therapeutics 6. WHIM Syndrome Late Stage Products (Phase II/III) 7. WHIM Syndrome Mid Stage Products (Phase II) 8. WHIM Syndrome Early Stage Products (Phase I) 9. WHIM Syndrome Preclinical Stage Products 10. WHIM Syndrome Therapeutics Assessment 11. WHIM Syndrome Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. WHIM Syndrome Key Companies 14. WHIM Syndrome Key Products 15. WHIM Syndrome Unmet Needs 16 . WHIM Syndrome Market Drivers and Barriers 17. WHIM Syndrome Future Perspectives and Conclusion 18. WHIM Syndrome Analyst Views 19. Appendix 20. About DelveInsight Related Reports: WHIM Syndrome Market https://www.delveinsight.com/report-store/whim-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr DelveInsight's 'WHIM Syndrome Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), WHIM Syndrome Epidemiology https://www.delveinsight.com/report-store/whim-syndrome-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr DelveInsight's 'WHIM Syndrome Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Latest Reports: •Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market •Cardiac Rhythm Management Devices Market: https://www.delveinsight.com/report-store/cardiac-rhythm-management-devices-market •Tumor Ablation Market: https://www.delveinsight.com/report-store/tumor-ablation-market •Fibromyalgia Market: https://www.delveinsight.com/report-store/fibromyalgia-market •Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market •India Healthcare Report: https://www.delveinsight.com/report-store/india-healthcare-outlook-report •Implantable Cardioverter Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market •Monkeypox Market: https://www.delveinsight.com/report-store/monkeypox-market •Antibody Drug Conjugate Market: https://www.delveinsight.com/report-store/antibody-drug-conjugate-market •Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services Contact Us: Gaurav Bora gbora@delveinsight.com +14699457679 Healthcare Consulting https://www.delveinsight.com/consulting-services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. This release was published on openPR.

Bokaro: Temperature dropped to 10-11 degrees Celsius amid light rainfall on Monday. The chill is intensified by brisk wind blowing at approximately 8 km/hour, affecting both day and night temperatures. The district administration is yet to implement winter relief measures such as arranging bonfires at key intersections and distributing blankets to the needy. Assistant director of social security, Piyush, said that the blanket procurement process is underway at the state headquarters. "Distribution will begin as soon as the tendering process is finalized," he said. Sources stated that the recent assembly elections have delayed the blanket procurement and distribution process across the state. "We are desperately waiting for blankets. It's extremely cold outside," said Vikas Kalindi, a rickshaw puller, in the city. Stay updated with the latest news on Times of India . Don't miss daily games like Crossword , Sudoku , and Mini Crossword .Iowa moves on without injured quarterback Brendan Sullivan when the Hawkeyes visit Maryland for a Big Ten Conference contest on Saturday afternoon. Former starter Cade McNamara is not ready to return from a concussion, so Iowa (6-4, 4-3) turns to former walk-on and fourth-stringer Jackson Stratton to lead the offense in College Park, Md. "Confident that he'll do a great job," Iowa coach Kirk Ferentz said of Stratton on his weekly radio show. "He stepped in, did a really nice job in our last ballgame. And he's got a good ability to throw the football, and he's learning every day. ... We'll go with him and see what we can do." Iowa had been on an upswing with Sullivan, who had sparked the Hawkeyes to convincing wins over Northwestern and Wisconsin before suffering an ankle injury in a 20-17 loss at UCLA on Nov. 8. Stratton came on in relief against the Bruins and completed 3 of 6 passes for 28 yards. Another storyline for Saturday is that Ferentz will be opposing his son, Brian Ferentz, an assistant at Maryland. Brian Ferentz was Iowa's offensive coordinator from 2017-23. "We've all got business to take care of on Saturday," Kirk Ferentz said. "I think his experience has been good and everything I know about it. As a parent, I'm glad he's with good people." Maryland (4-6, 1-6) needs a win to keep its hopes alive for a fourth straight bowl appearance under Mike Locksley. The Terrapins have dropped five of their last six games, all by at least 14 points, including a 31-17 loss at home to Rutgers last weekend. "It's been a challenging last few weeks to say the least," Locksley said. The challenge this week will be to stop Iowa running back Kaleb Johnson, who leads the Big Ten in rushing yards (1,328) and touchdowns (20), averaging 7.1 yards per carry. "With running backs, it's not always about speed. It's about power, vision and the ability to make something out of nothing," Locksley said. "This guy is a load and runs behind his pads." Maryland answers with quarterback Billy Edwards Jr., who leads the Big Ten in passing yards per game (285.5) and completions (268). His top target is Tai Felton, who leads the conference in catches (86) and receiving yards (1,040). --Field Level Media

Doctored images have been around for decades. The term "Photoshopped" is part of everyday language. But in recent years, it has seemingly been replaced by a new word: deepfake. It's almost everywhere online, but you likely won't find it in your dictionary at home. What exactly is a deepfake, and how does the technology work? RELATED STORY | Scripps News Reports: Sex, Lies, and Deepfakes A deepfake is an image or video that has been generated by artificial intelligence to look real. Most deepfakes use a type of AI called a "diffusion model." In a nutshell, a diffusion model creates content by stripping away noise. "With diffusion models, they found a very clever way of taking an image and then constructing that procedure to go from here to there," said Lucas Hansen said. He and Siddharth Hiregowdara are cofounders of CivAI, a nonprofit educating the public on the potential — and dangers — of AI. How diffusion models work It can get complicated, so imagine the AI – or diffusion model – as a detective trying to catch a suspect. Like a detective, it relies on its experience and training. It recalls a previous case -– a sneaky cat on the run. Every day it added more and more disguises. On Monday, no disguise. Tuesday, it put on a little wig. Wednesday, it added some jewelry. By Sunday, it's unrecognizable and wearing a cheeseburger mask. The detective learned these changes can tell you what it wore and on what day. AI diffusion models do something similar with noise, learning what something looks like at each step. "The job of the diffusion model is to remove noise," Hiregowdara said. "You would give the model this picture, and then it will give you a slightly de-noised version of this picture." RELATED STORY | Scripps News got deepfaked to see how AI could impact elections When it's time to solve the case and generate a suspect, we give it a clue: the prompts we give when we create an AI-generated image. "We have been given the hint that this is supposed to look like a cat. So what catlike things can we see in here? Okay, we see this curve, maybe that's an ear," Hiregowdara said. The "detective" works backward, recalling its training. It sees a noisy image. Thanks to the clue, it is looking for a suspect — a cat. It subtracts disguises (noise) until it finds the new suspect. Case closed. Now imagine the "detective" living and solving crimes for years and years. It learns and studies everything — landscapes, objects, animals, people, anything at all. So when it needs to generate a suspect or an image, it remembers its training and creates an image. Deepfakes and faceswaps Many deepfake images and videos employ some type of face swapping technology. You've probably experienced this kind of technology already — faceswapping filters like on Snapchat, Instagram or Tiktok use technology similar to diffusion models, recognizing faces and replacing things in real time. "It will find the face in the image and then cut that out kind of, then take the face and convert it to its internal representation," Hansen said. The results are refined then repeated frame by frame. The future and becoming our own detectives As deepfakes become more and more realistic and tougher to detect, understanding how the technology works at a basic level can help us prepare for any dangers or misuse. Deepfakes have already been used to spread election disinformation, create fake explicit images of a teenager, even frame a principal with AI-created racist audio. "All the netizens on social media also have a role to play," Siwei Lyu said. Lyu is a SUNY Empire Innovation Professor at the University of Buffalo's Department of Computer Science and Engineering, and the director of the Media Forensics Lab. His team has created a tool to help spot deepfakes called "DeepFake-o-meter." "We do not know how to handle, how to deal, with these kinds of problems. It's very new. And also requires technical knowledge to understand some of the subtleties there," Lyu said. "The media, the government, can play a very active role to improve user awareness and education. Especially for vulnerable groups like seniors, the kids, who will start to understand the social media world and start to become exposed to AI technologies. They can easily fall for AI magic or start using AI without knowing the limits." RELATED STORY | AI voice cloning: How programs are learning to pick up on pitch and tone Both Lyu and CivAI believe in exposure and education to help combat any potential misuse of deepfake technology. "Our overall goal is that we think AI is going t impact pretty much everyone in a lot of different ways," Hansen said. "And we think that everyone should be aware of the ways that it's going to change them because it's going to impact everyone." "More than just general education — just knowing the facts and having heard what's going to happen," he added. "We want to give people a really intuitive experience of what's going on." Hansen goes on to explain CivAI's role in educating the public. "We try and make all of our demonstrations personalized as much as possible. What we're working on is making it so people can see it themselves. So they know it's real, and they feel that it's real," Hansen said. "And they can have a deep gut level feel for tthe impact that it's going to have." "A big part of the solution is essentially just going to be education and sort of cultural changes," he added. "A lot of this synthetic content is sort of like a new virus that is attacking society right now, and people need to become immune to it in some ways. They need to be more suspicious about what's real and what's not, and I think that will help a lot as well."TAMPA, Fla. (AP) — Tampa Bay’s surest path to the NFL playoffs is a division championship. The Buccaneers will need help to repeat in the NFC South , but only if they first and foremost give themselves a chance. That means winning their remaining games at home against Carolina and New Orleans, while the Atlanta Falcons lose at least once in the final two weeks of the regular season. The Bucs (8-7) and Falcons share the best record in the division, however Atlanta holds the tiebreaker after sweeping the season series between the teams. Tampa Bay, which has won three consecutive division titles, is the only NFC team that has made the playoffs each of the past four seasons. “We’ve got to take care of business or else we’ve got no shot,” quarterback Baker Mayfield said after a 26-24 loss at Dallas cost the Bucs control of the NFC South race. “This one, we’ve got to take it on the chin,” Mayfield added. “It’s a short week. It’s Christmas week. We’ve got to focus on Carolina and figure out a way to win.” If Atlanta is able to maintain its lead, Tampa Bay could make the postseason as a wild card if the Bucs win out and the Commanders lose twice. Coach Todd Bowles sounds confident that his players understand the challenge ahead and will clean up mistakes that contributed to the end of their four-game win streak. “We’ve got to win a ballgame (this week). If we don’t win a ballgame, we don’t give ourselves a chance,” Bowles said Monday. “We have to focus on us like we’ve been doing,” the coach added. “We have to correct the mistakes, and we have to go out and win Sunday, and we’ve got to win the next week, and then we’ll see what happens after that.” What’s working The offense, which ranks third in the NFL at 389.8 yards per game, isn’t a fluke. Despite losing to the Cowboys, Tampa Bay finished with 410 yards total offense. It was the team’s fifth straight game — as well as an NFL-high ninth overall — with 400-plus yards. The Bucs are seventh in rushing (143.7 yards per game) after ranking 32nd each of the past two seasons. What needs helps The defense yielded 292 yards passing against the Cowboys, 226 of it in the first half when Cowboys WR CeeDee Lamb had six catches for 100 yards and a touchdown. Bowles said shoddy tackling was the biggest issue — not poor coverage. Lamb had one reception for 5 yards after halftime. Stock up Mayfield’s chemistry with rookie WR Jalen McMillan, who has 27 receptions for 336 yards and five TDs, continues to grow. McMillan had five catches for 57 yards and a touchdown — his fourth in the past three games — against Dallas. He was also the intended receiver on Mayfield’s deep throw that CB Jourdan Lewis intercepted in the end zone to help the Cowboys hold off the Bucs in the closing minutes. Stock down Turnovers were costly against Dallas. The end-zone interception stopped the Bucs from cutting into a 26-17 deficit with 6:22 remaining in the fourth quarter. Rachaad White’s fumble with 1:31 left ended any hope for a last-minute victory. On both plays, defenders ripped the ball out of the grasp of the offensive player. “We knew they were going to rake at the ball going into the ballgame,” Bowles said. “We just have to have two hands on the ball, and we have to fight for it. We have to take better care of the football. That’s priority No. 1.” Injuries Bowles said it’s too early to project the status of several starters for coming games, including S Antoine Winfield Jr. (knee), who has missed the past two games. TE Cade Otton (knee) and LB K.J. Britt (ankle) were inactive against the Cowboys, while reserve WR Sterling Shepard left during the game with a hamstring injury. Key number 80. Bucky Irving leads all NFL rookie RBs with 920 yards rushing. He needs 80 over the next two games to reach 1,000. He scored his seventh rushing touchdown against Dallas. That tied Errict Rhett and Lars Tate for the second-most rushing TDs by a rookie running back in franchise history. Doug Martin set the record of 11 in 2012. Next up Host Carolina on Sunday. ___ NFL: https://apnews.com/hub/nfl

Solaris Energy Infrastructure, Inc. Announces Commencement of Underwritten Public Offering of Class A Common StockThe cyber climate shifts resilience thinkingHow the revolving door at FAA spins Boeing’s way

Nuggets could go 'all-in' with blockbuster trade for Heat's $146 million superstar | Sporting NewsDONALD Trump was urged to return to his late mum’s Scots home with a “fistful” of investment cash. Islanders on Lewis are said to “cringe” at their ties to the US President-elect, 78. Advertisement 3 President-elect Donald Trump 3 Councillor John MacIver says a cash investment by Trump might make islanders see him in a different light But they said the controversial businessman — who last month secured a second White House term — could be welcomed back if he agreed to pump money into the Western Isles. Councillor John MacIver said: “You just cringe when you see another story about Donald. “When he first stood for office, it was a big thing for the island to have the connection. "But it’s been such a disappointment, really — the way he is and the way he treats people. Advertisement read more donald trump TRUMP TALK Wills will be tight-lipped with Trump - they disagree on so much, expert says TRUMP CARD Donald Trump files motion to dismiss hush money case after Hunter Biden pardon “If he came with a fistful of dollars to support various island projects, maybe we’d see him in a different light.” Mr Trump visited his mum Mary Anne’s former home in the village of Tong in 2008. His sister, US judge Maryanne Trump Barry, previously donated £158,000 to the Bethesda Care Home on Stornoway. She died last year. Advertisement Most read in Money LEAVING TOWN High street giant to shut branch as mystery surrounds shopping centre future CHOC FULL Shoppers rush to buy Cadbury selection boxes at major supermarket for just £1 CASH FLOODS Hardy shoppers defy Storm Darragh to queue for a new Poundland ANN-OTHER ONE Major high street retailer to close store for good and 'all stock must go' Mr MacIver stressed: “We’ve got happy memories of his mother and his sister but nobody has got any connection with Donald himself. "He didn’t do much for the islands.” Prince William shakes hands with Donald Trump as Notre Dame reopens We told how the New Yorker is set to visit Aberdeenshire next year for the opening of his new golf course. Son Eric suggested his “love” for the family’s homeland kept him investing here. Advertisement Mr Trump’s Scots representatives were asked for comment. 3 Tycoon Donald Trump pictured at the house in Tong, on the Isle of Lewis, where his mother was brought up before she emigrated to the United States.

Bethlehem plans another somber Christmas under the shadow of war in GazaNothing's guaranteed, but Bucs need to win out to give themselves best shot to make the playoffs

After-hours movers: Marvell Technology, Salesforce, Okta and moreSAN DIEGO , Dec. 23, 2024 /PRNewswire/ -- CreateAI Holdings Inc., formerly TuSimple Holdings Inc. (OTCMKTS: TSPH) ("CreateAI" or the "Company"), a global artificial intelligence technology company, today announced shareholder voting results for its annual meeting of stockholders held on December 20, 2024 (the "Annual Meeting"). As of October 28, 2024 , the record date for the Annual Meeting, there were a total of 232,618,399 shares of common stock outstanding and entitled to vote at the Annual Meeting, comprised of 208,618,399 shares of Class A Common Stock (each with one vote per share) and 24,000,000 shares of Class B Common Stock (each with ten votes per share). At the Annual Meeting, holders of 207,347,538 shares of common stock, representing 423,347,538 votes, entitled to vote at the meeting were represented in person or by proxy and, therefore, a quorum constituted of the majority of the voting power of the shares of common stock issued and outstanding and entitled to vote at the Annual Meeting was present. The following is a brief description of each matter voted upon at the 2024 Annual Meeting and the numbers of votes cast for, withheld, or against, the number of abstentions, and the number of broker non-votes with respect to each other, as applicable. 1. Election of six nominees to serve on the Board of Directors (the "Board") for a term which will expire at the 2025 annual meeting of stockholders, or, if Proposal Two is adopted, to hold office until the annual meeting of stockholders in accordance with the class of director to which each nominee will be assigned. The following six directors were elected by the votes as indicated below. For Withheld Broker Non-Votes Cheng Lu 208,949,915 164,765,019 1 49,632,604 Mo Chen 208,946,146 164,768,788 1 49,632,604 James Lu 209,109,928 164,605,006 1 49,632,604 Zhen Tao 209,158,316 164,556,618 1 49,632,604 Albert Schultz 348,895,019 1 24,819,915 49,632,604 Jianan Hao 209,021,652 164,693,282 1 49,632,604 The totals above include the 240,000,000 votes represented by the Class B shares of Common Stock. 12,000,000 shares of Class B Common Stock (representing 120,000,00 votes) were voted "FOR" and 12,000,000 shares of Class B Common stock (representing 120,000,00 votes) were voted "WITHHELD" for each of the Directors other than Albert Schultz . All shares of Class B Common Stock were voted "FOR" the election of Albert Schultz . Excluding the 240,000,000 votes from the 24,000,000 shares of Class B Common Stock from the totals above, the 183,347,538 shares of Class A Common Stock were voted as indicated below. For Withheld Broker Non-Votes Cheng Lu 88,949,915 44,765,019 49,632,604 Mo Chen 88,946,146 44,768,788 49,632,604 James Lu 89,109,928 44,605,006 49,632,604 Zhen Tao 89,158,316 44,556,618 49,632,604 Albert Schultz 108,895,019 24,819,915 49,632,604 Jianan Hao 89,021,652 44,693,282 49,632,604 2. Amendment to the Company's Restated Certificate of Incorporation to classify the Board of Directors into three classes, with directors in each class to serve staggered three-year terms. Pursuant to the Restated Certificate of Incorporation, Proposal Two must receive the affirmative vote of the holders of at least a majority of the voting power of all of the then-outstanding shares of the capital stock of the Company entitled to vote generally in the election of directors, voting together as a single class, since directors representing two-thirds (2/3) of the total number of authorized directors have already approved. The amendment was not approved 2 by the votes as indicated below: For Against 1 Abstain Broker Non-Votes 208,955,668 164,659,652 99,614 49,632,604 Because Proposal Two was not approved, the six directors elected pursuant to Proposal One will serve on the Board for a term which will expire at the 2025 annual meeting of stockholders. 3. Ratification of the appointment of UHY LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 . The selection was ratified by the votes as indicated below: For Against 1 Abstain Broker Non-Votes 255,504,371 155,923,768 11,919,399 - Note 1: Includes 120,000,000 votes of the 12,000,000 shares of Class B Common Stock held by White Marble LLC and White Marble International Limited (together, the "White Marble Entities") controlled by Dr. Xiaodi Hou . Note 2: The White Marble Entities have filed an action in the Delaware Court of Chancery seeking a declaratory judgment that the voting agreement between White Marble and Mo Chen is invalid and White Marble, not Mo Chen , controls the vote. White Marble LLC v. Chen , C.A. No. 2024-1208-PAF (Del. Ch.) On December 13, 2024 , the Court entered an order that allows the Company to hold the vote on Proposal Two, and ordered that if Proposal Two is not approved at the Annual Meeting but the Court determines in the Action that Mo Chen , not the White Marble Entities, control how the White Marble Entities' Shares are voted, then the White Marble Entities' shares shall be deemed to have been voted in favor of Proposal Two at the Annual Meeting and that such vote shall stand. The vote totals above include the votes of the shares held by the White Marble Entities as voted by the White Marble Entities. If the shares held by the White Marble entities reflected in the totals above are deemed to have been voted in favor of Proposal Two, the Proposal will have passed. Accordingly, if the Court rules in Mo Chen's favor, Proposal Two will be deemed to have passed and the Company would be permitted to amend its Certificate of Incorporation to implement Proposal Two and each of the directors elected pursuant to Proposal One will serve on the Board until the annual meeting of stockholders in accordance with the class of director to which each nominee is assigned. About CreateAI CreateAI (formerly TuSimple) is a global artificial intelligence company with offices in US, China , and Japan . The company is pioneering the future of digital entertainment content production, seamlessly blending cutting-edge generative AI technology with the creativity of world-class talent. Our mission is to redefine the boundaries of what's possible in digital storytelling by developing immersive, captivating, and visually stunning experiences that resonate with audiences on a global scale. Investor Relations Contact: ICR for CreateAI CreateAI.IR@icrinc.com View original content to download multimedia: https://www.prnewswire.com/news-releases/createai-announces-results-of-2024-annual-meeting-of-stockholders-302338618.html SOURCE CreateAI Holdings Inc

Hacker scores 21, Bellarmine beats NAIA Brescia 94-66

Qatar tribune Agencies US consumer spending increased in November amid strong demand for a range of goods and services, underscoring the economy’s resilience, which saw the Federal Reserve this week projecting fewer interest rate cuts in 2025 than it had in September. There was also good news on inflation last month after a series of warmer readings. The report from the Commerce Department on Friday showed moderate monthly rises in prices, with a measure of underlying inflation posting its smallest gain in six months. Nonetheless, the annual increase in core inflation, excluding food and energy, remained stubbornly well above the US central bank’s 2 percent target. There are also worries that plans by President-elect Donald Trump’s incoming administration to cut taxes, impose or raise tariffs on imports and deport millions of undocumented immigrants would stoke inflation. “The economy continues to grow from strong consumer demand as income growth and the wealth effect from higher portfolio values give consumers capacity to spend,” said Jeffrey Roach, chief economist at LPL Financial. “Inflation was more benign than expected but the stickiness of some categories supports the Fed’s hesitancy to materially lower rates next year.” Consumer spending, which accounts for more than two-thirds of US economic activity, rose 0.4 percent last month after a downwardly revised 0.3 percent gain in October, the Commerce Department’s Bureau of Economic Analysis said. Economists polled by Reuters had forecast consumer spending advancing 0.5 percent after a previously reported 0.4 percent rise in October. The nearly broad-based increase in spending was led by new motor vehicles, likely in part as households replaced vehicles damaged during Hurricanes Helene and Milton. That accounted for the bulk of the 0.8 percent rebound in goods outlays. Spending on recreational goods and vehicles also rose as did outlays on financial services and insurance, mostly charges, fees and commissions. There was also increased spending on recreation services, healthcare, clothing and footwear, furniture as well as housing and utilities. Spending at restaurants and bars as well as on hotel and motel stays also increased. Spending on services rose 0.2 percent. When adjusted for inflation, consumer spending rose 0.3 percent after edging up 0.1 percent in October. The so-called real consumer spending is running at an annualized rate of 3.1 percent in the first two months of the fourth quarter. “That will lay the foundation for another very solid GDP number for the fourth quarter,” said Lou Crandall, chief economist at Wrightson ICAP. Consumer spending surged at a 3.7 percent pace in the third quarter, the fastest in 1-1/2 years, helping to propel the economy to a 3.1 percent growth rate following a 3.0 percent pace of expansion in the April-June quarter. The Atlanta Fed is forecasting gross domestic product increasing at a 3.1 percent rate in the fourth quarter. Fed Chair Jerome Powell on Wednesday described the economy as having “just been remarkable,” adding “I feel very good about ... the performance of the economy and we want to keep that going.” The central bank on Wednesday cut its benchmark overnight interest rate by 25 basis points to the 4.25 percent-4.50 percent range. It forecast only two rate reductions in 2025, in a nod to the economy’s continued resilience and still-high inflation. In September, Fed officials had forecast four quarter-point rate cuts next year. The shallower rate cut path in the latest projections also reflected uncertainty over policies from the incoming Trump administration. Stocks on Wall Street traded higher. The dollar slipped against a basket of currencies. US Treasury yields fell. Labor market stamina, marked by low layoffs and strong wage growth, is underpinning consumer spending. Strong household balance sheets, reflecting high stock market and home prices are also driving spending. Household savings remain supportive. Economists, however, cautioned that it was mostly middle- and higher-income households that were benefiting from the wage gains and wealth effects, noting that lower-income consumers were under financial pressure. Personal income rose 0.3 percent, with wages shooting up 0.6 percent. Income at the disposal of households after accounting for inflation rose 0.2 percent, meaning some tapped their savings to fund purchases. The saving rate dipped to 4.4 percent from 4.5 percent in October. Economists did not believe that the moderation in inflation last month would have changed the tone of the Fed’s message on Wednesday. Copy 24/12/2024 10The Shocking Drop! Why Indie Semiconductor’s Stock Plummeted

NEW YORK , Dec. 10, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Dentsply Sirona Inc. (NASDAQ: XRAY) between December 1, 2022 and November 6, 2024 , both dates inclusive (the "Class Period"), of the important January 27, 2025 lead plaintiff deadline. So what: If you purchased Dentsply common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the Dentsply class action, go to https://rosenlegal.com/submit-form/?case_id=31762 or call Phillip Kim, Esq. at 866-767-3653 or email case@rosenlegal.com for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 13 , 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the case: According to the lawsuit, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Dentsply targeted low-income people who did not have access to good oral hygiene education, a dentist, or dental insurance, which often meant patients signing up for Byte, a direct-to-consumer ("DTC") aligner solution, had underlying dental issues that would have made them ineligible for treatment; (2) the push for Byte growth and sales commissions caused sales employees to sell to contraindicated patients; (3) as a result of the above, the Byte patient onboarding workflow did not provide adequate assurance that contraindicated patients did not enter treatment; (4) before and during the Class Period, reports of Byte patient injuries were pouring in; (5) Dentsply knew that its Byte aligners were causing severe patient injuries for years but did little to investigate those injuries or notify the U.S. Food and Drug Administration ("FDA"); (6) Dentsply had no systems in place to notify the FDA of these injuries, which Dentsply is required to do within 30 days of learning of a problem; (7) the FDA had received a sharp uptick in reports of serious injuries from Byte patients; (8) as a result of the above, Dentsply materially overstated the goodwill value of Byte; and (9) as a result of the above, defendants' positive statements about Dentsply's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Dentsply class action, go to https://rosenlegal.com/submit-form/?case_id=31762 mailto: or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ . Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@rosenlegal.com www.rosenlegal.com View original content to download multimedia: https://www.prnewswire.com/news-releases/xray-investors-have-opportunity-to-lead-dentsply-sirona-inc-securities-fraud-lawsuit-302327941.html SOURCE THE ROSEN LAW FIRM, P. A.

President-elect Donald Trump’s lawyers urge judge to toss his hush money convictionIslanders hope to win third straight when Kings roll into town